Boehringer Ingelheim is all set to publish within the next weeks their clinical trials information online. All confirmatory trials initiated on or after July 1, 2005 will be made public by posting information prior to start of patient enrolment in a trial repository maintained by the National Library of Medicine in the US.
In addition to posting all clinically directive phase II-IV clinical trials at “www.clinicaltrials.gov”, Boehringer Ingelheim will publish the results of these trials on a company web page for products commercially available in at least one country.
For products developed or marketed under collaboration with other companies, Boehringer Ingelheim agreed with its partners that the license holder would be responsible for providing information. All trials initiated on or after July 1, 2005 will be submitted to the registry. In addition, all ongoing clinical trials will be posted not later than September 13, 2005.
“In line with an announcement of the International Federation of Pharmaceutical Manufacturers Associations earlier this year, Boehringer Ingelheim is committed to offer as much transparency as possible on our clinical trials to doctors, nurses, pharmacists, patients and all other interested parties. At one central location everybody will be able to access key information on confirmatory clinical trials, including medical conditions being studied, number of patients and centres, as well as trial timelines. We are sure that this approach offers health care personnel and patients the possibility to find out more about the drug they started to use or drugs that are yet to be marketed,” said Dr. Andreas Barner, member of the Board of Managing Directors of Boehringer Ingelheim and responsible for Research, Development and Medicine.
Results of completed trials will be made available on the Boehringer Ingelheim web page within one year after the drug is first approved and marketed in any country or within one year after trial completion. In addition once the IFPMA portal has been launched Boehringer Ingelheim’s clinical trial information for both ongoing and completed trials will also be assessable via the IFPMA portal.